Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering CorMedix (CRMD) , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this pharmaceutical and medical device company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 24.71%, on average, in the last two quarters.For the last reported quarter, CorMedix came ...

DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a changing earnin ...

MONSEY, N.Y., July 14, 2025 (GLOBE NEWSWIRE) --  The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Monogram Technologies, Inc. (Nasdaq: MGRM) (“Monogram”) to Zimmer Biomet for an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share in cash if certain product development, regulatory, and revenue milestones are achieved through 2030. At least two investors have already express ...

Harrow (HROW) shares soared 11.4% in the last trading session to close at $34.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.7% gain over the past four weeks.The sudden rise in the share price of Harrow can be attributed to the positive investor mindset regarding the continued sales growth of its innovative opthalmic pharmaceutical products in the North American market, which is expected to further boost shareholder value. ...

Agenus (AGEN) shares ended the last trading session 19.3% higher at $7.06. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 22.8% gain over the past four weeks.Earlier this month, the company announced encouraging clinical data for its combination therapy of botensilimab and balstilimab (BOT/BAL) in patients with microsatellite-stable metastatic colorectal cancer without active liver metastases. In an expanded cohor ...

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 billion, representing an increase of 6.7% year over year.The current level reflects a downward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Ahea ...

CHONGQING, CHINA - JULY 13: In this photo illustration, a smartphone displaying the logo of Johnson ... More & Johnson (NYSE: JNJ), a leading American multinational corporation known for pharmaceuticals, medical devices, and consumer health products, is held in front of a screen showing the company's latest stock market chart on July 13, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)Getty Images Johnson & Johnson (NYSE:JNJ) is set to report its earnings on Wednesday, July 16, 2025. ...

Key Takeaways ABT's Q2 revenues are projected at $11.07B, up 6.7% year over year; EPS is estimated to rise 9.6% to $1.25. ABT's Medical Devices likely drove growth, led by CGMs, cardiac devices and TMVR system approval. Nutrition and EPD segments are expected to post modest to solid year-over-year revenue gains. Abbott Laboratories (ABT) is slated to report second-quarter 2025 results on July 17, before the opening bell.The company delivered adjusted earnings per share (EPS) of $1.09 in the last quarter, ...

Key Takeaways BIO unveils four new ddPCR systems, enhancing its Life Science offerings post-Stilla Technologies acquisition. BIO's new systems improve workflow, precision and throughput across PCR applications in key research areas. BIO sees strong adoption of ddPCR tools, aided by recent investments and platform expansions in 2024.Bio-Rad Laboratories (BIO) recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ...

Kennewick, WA, July 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide TherapyTM (PRnT) solutions, today announced the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel®, a novel hydrogel-based radioactive therapy designed to deliver targeted radiation to solid tumors. This comprehensive submission, supported by extensive animal and human data, marks a significant milestone in Vivos Inc.’s ...